Rest Of Europe Chemiluminescence Immunoassay Market (2026-2031)
The Rest Of Europe Chemiluminescence Immunoassay Market was valued at $469.4 Million in 2026 and projected to reach to $658 Million by 2031, representing a compound annual growth rate of 7.0%. Rest Of Europe's chemiluminescence immunoassay market is poised for steady growth through 2031, supported by modernization of healthcare infrastructure and increasing laboratory automation across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe Chemiluminescence Immunoassay Market Trends and Insights
- This steady expansion reflects increasing adoption of advanced diagnostic technologies across Rest Of Europe's healthcare systems, driven by rising demand for rapid, sensitive immunoassay testing in clinical laboratories and point-of-care settings.
- Rest Of Europe benefits from strong regulatory frameworks and growing investment in healthcare infrastructure that support the deployment of chemiluminescence-based diagnostic platforms. The market growth in Rest Of Europe is underpinned by aging populations, higher prevalence of chronic diseases, and the shift toward automation in laboratory diagnostics.
- Rest Of Europe's healthcare providers are increasingly recognizing the clinical and operational advantages of chemiluminescence immunoassay systems, including improved turnaround times and reduced manual intervention.
- Between 2026 and 2031, Rest Of Europe is expected to see accelerated adoption among mid-sized and smaller diagnostic centers seeking cost-effective, high-throughput solutions..
Key Market Statistics
- CAGR (2026-2031) 7.0% CAGR
- Market Size, 2026 ~USD 469.4 Million
- Forecast, 2031 ~USD 658 Million
- Country Rest Of Europe
Rest Of Europe Chemiluminescence Immunoassay Market Overview
Market Valuation Growth :
Rest Of Europe's chemiluminescence immunoassay market is valued at USD 469.4 million in 2026 and is projected to reach USD 658.0 million by 2031, demonstrating robust market expansion.
Consistent CAGR Performance :
The region is experiencing a steady 7.0% CAGR from 2026 to 2031, slightly below the global average of 7.2%, indicating stable but measured growth in diagnostic adoption.
Healthcare Technology Adoption :
Increasing adoption of advanced diagnostic technologies across Rest Of Europe's healthcare systems is driving demand for rapid and sensitive immunoassay testing solutions.
Diagnostic Testing Demand :
Rising healthcare expenditure and emphasis on early disease detection in Rest Of Europe are accelerating the uptake of chemiluminescence immunoassay platforms in clinical laboratories.
Rest Of Europe Chemiluminescence Immunoassay Market Dynamics
- Healthcare providers are investing in advanced diagnostic capabilities to improve patient outcomes and operational efficiency, creating sustained demand for high-sensitivity immunoassay technologies. The market's 7.0% CAGR reflects a balanced growth trajectory driven by regulatory support for diagnostic innovation and rising awareness of precision medicine.
- Key growth drivers include aging populations requiring enhanced diagnostic screening, integration of chemiluminescence systems into hospital networks, and expanding private laboratory sectors across Rest Of Europe's diverse healthcare markets..
Related Ecosystem
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- Rest Of Europe's chemiluminescence immunoassay market will grow from USD 469.4 million (2026) to USD 658.0 million (2031) at a 7.0% CAGR.
- Rest Of Europe's healthcare infrastructure modernization and aging demographics are primary drivers of market expansion through 2031.
- Rest Of Europe is experiencing increased adoption of automated chemiluminescence systems in both large hospital networks and smaller diagnostic laboratories.
- Rest Of Europe's regulatory environment and reimbursement policies support sustained investment in advanced immunoassay diagnostic technologies.
Chemiluminescence Immunoassay Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | ONCOLOGY (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 7.2% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product Type) |
| Market Size Base Year (Billions) | ~USD 11.58 (2026) |
| Revenue Forecast (Billions) | ~USD 16.39 (2031) |
| Segments Covered | Product Type, Technology, Sample Type, Application, End User |
Rest Of Europe Chemiluminescence Immunoassay Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product Type
- Consumables
- Instruments
By Technology
- Chemiluminescence Enzyme Immunoassays (Cleia)
- Electrochemiluminescence Immunoassays (Ecli)
- Microparticle Chemiluminescence Immunoassays
By Sample Type
- Blood
- Other Sample Types
- Saliva
- Urine
By Application
- Allergy Diagnostics
- Autoimmune Disorders
- Blood Screening
- Bone & Mineral Disorders
- Cardiology
- Endocrinology
- Gastroenterology
- Infectious Diseases
- Metabolic Disorders
- Neurology
- Newborn Screening
- Oncology
- Other Applications
- Respiratory Diseases
- Therapeutic Drug Monitoring
- Toxicology
By End User
- Clinical Laboratories
- Hospitals
- Other End Users
- Pharmaceutical & Biotechnology Companies And Cros
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies need Rest Of Europe-specific market data to develop regional product strategies, pricing models, and distribution partnerships aligned with local healthcare requirements.
- Healthcare System Administrators : Hospital networks and laboratory directors require market insights to justify capital investments in chemiluminescence immunoassay systems and optimize diagnostic service offerings.
- Medical Device Investors : Private equity and venture capital firms evaluating diagnostic technology investments need regional market sizing and growth projections to assess Rest Of Europe opportunities.
- Clinical Laboratory Operators : Independent and hospital-based laboratories need competitive intelligence on market trends and technology adoption to enhance service capabilities and operational efficiency.
- Healthcare Consultants & Analysts : Management consulting firms and market research professionals require detailed regional data to support client advisory services and strategic planning initiatives across Rest Of Europe.
Key Companies in the Rest Of Europe Chemiluminescence Immunoassay Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and bioproduction solutions),Life Sciences (instruments, genomics, and research tools),Diagnostics (clinical instruments and consumables), |
| DIASORIN S.P.A. | Italy | Public Company | LIAISON XL / LIAISON XS immunodiagnostics,Molecular diagnostics (Simplexa, congenital CMV, LIAISON PLEX assays),xMAP technology platform and related IVD solutions, |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Point of Care,Transfusion Medicine, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers & reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems & reagents,Blood gas / electrolyte / urinalysis, |
| SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. | China | Public Company | Immunoassay analyzers and reagents,Biochemistry/Electrolyte systems and reagents,Integrated systems and lab automation, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls, PVC chain, and petrochemicals (VCM, ethylene, propylene, aromatics),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia, beads), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Consumables,Informatics and Software, |
| SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. | China | Public Company | Patient monitoring & life support (incl. ventilators, anesthesia, defibrillation, infusion),Ultrasound & medical imaging (incl. radiology, emergency ultrasound, endoscope camera systems),In-vitro diagnostics (CLIA, chemistry, hematology), |
ABBOTT
Abbott is a United States-based public company founded in 1888 with 115,000 employees, operating in the healthcare and pharmaceutical sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and diagnostics.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating across diversified industrial and life sciences sectors.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees engaged in in vitro diagnostics and molecular diagnostics.
QUIDELORTHO CORPORATION
QuidelOrtho Corporation is a United States-based public company founded in 1979 with 6,500 employees specializing in diagnostic solutions.
SYSMEX CORPORATION
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees focused on in vitro diagnostics and hematology systems.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Shenzhen New Industries Biomedical Engineering Co., Ltd. is a Chinese public company founded in 1995 with 2,785 employees operating in the biomedical diagnostics sector.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees engaged in specialty chemicals and diagnostics.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees providing life science research and clinical diagnostics products.
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a Chinese public company founded in 1991 with 21,288 employees manufacturing medical devices and diagnostics equipment.
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuation data specific to Rest Of Europe, enabling accurate budget allocation and investment decisions for regional expansion strategies.
- Growth Trajectory Insights : Understand the 7.0% CAGR trajectory and USD 188.6 million growth opportunity from 2026-2031 to identify optimal market entry and scaling timelines.
- Competitive Positioning : Benchmark your organization against regional market dynamics and adoption patterns to develop targeted go-to-market strategies for Rest Of Europe's healthcare sector.
- Technology Adoption Trends : Gain insights into healthcare system modernization patterns and diagnostic technology preferences across Rest Of Europe's diverse markets and regulatory environments.
- Strategic Planning Data : Access actionable intelligence on regional demand drivers, healthcare infrastructure investments, and laboratory automation trends to inform product development and market positioning.
Frequently asked questions
What is the market size of chemiluminescence immunoassay in Rest Of Europe?
Rest Of Europe's chemiluminescence immunoassay market is estimated at USD 469.4 million in 2026 and is forecast to reach USD 658.0 million by 2031.
What is the expected growth rate for Rest Of Europe's chemiluminescence immunoassay market?
Rest Of Europe's chemiluminescence immunoassay market is expected to grow at a CAGR of 7.0% from 2026 to 2031.
What factors are driving growth in Rest Of Europe's chemiluminescence immunoassay market?
Rest Of Europe's market growth is driven by aging populations, increased chronic disease prevalence, healthcare infrastructure modernization, and the shift toward laboratory automation and high-throughput diagnostic solutions.
Which healthcare settings in Rest Of Europe are adopting chemiluminescence immunoassay systems?
Rest Of Europe's adoption spans large hospital networks, mid-sized diagnostic centers, smaller clinical laboratories, and point-of-care facilities seeking rapid and reliable immunoassay testing capabilities.
How does Rest Of Europe's regulatory environment impact the chemiluminescence immunoassay market?
Rest Of Europe's strong regulatory frameworks and favorable reimbursement policies create a supportive environment for the adoption and investment in advanced chemiluminescence immunoassay diagnostic platforms.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the size of the CLIA market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and companies' SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the CLIA market. It was also used to obtain important information on key players, market classification, and segmentation aligned with industry trends to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after secondary research provided information on the CLIA market. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief Executive Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, and product development/innovation teams, as well as related key executives from manufacturers and distributors operating in the CLIA market.; and key opinion leaders.
Primary interviews were conducted to gather insights into market statistics, revenue from products and services, market breakdowns, market size estimates, market forecasting, and data triangulation. Primary research also helped in understanding the various trends in technology, applications, verticals, and regions. Stakeholders from the demand side, customers/end users who are using infection control products, were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.
The following is a breakdown of the primary respondents:
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primaries include sales managers, marketing managers, and product managers.
Note 3: Companies are classified into tiers based on their total revenue.
As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The research methodology used to estimate the size of the CLIA market includes the following details.
The market sizing was conducted on a global basis.
Country-level Analysis: The size of the CLIA market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall CLIA market was obtained from secondary data and validated by primary participants to arrive at the total CLIA market. Primary participants further validated the numbers.
Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end user and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall CLIA market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.
Global Chemiluminescence Immunoassay Market : Top-Down and Bottom-Up Approach
Data Triangulation
The market was split into several segments and subsegments after determining the overall market size, using the market sizing processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for each market segment and subsegment. The data was triangulated by examining various factors and trends on both the demand and supply sides of the CLIA market.
Market Definition
Chemiluminescent immunoassay (CLIA) is an immunoassay technique in which the label, i.e., the indicator of the analytical reaction, is a luminescent molecule. CLIA is a variation of the standard enzyme immunoassay (EIA), a biochemical technique used in immunology. This variation technique can be used for medical diagnosis and in several other industries for various applications. In recent years, CLIA has attracted increasing attention across fields such as clinical diagnosis, life sciences, food safety, environmental monitoring, and pharmaceutical analysis, due to its high specificity, high sensitivity, broad applicability, simple instrumentation, and wide linear range.
Key Stakeholders
- CLIA manufacturers and distributors
- CLIA analyzers & consumables manufacturers
- Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies)
- Healthcare institutions (hospitals and outpatient clinics)
- Distributors and suppliers
- Research institutes
- Health insurance payers
- World Health Organization (WHO)
- Organisation for Economic Co-operation and Development (OECD)
- National Institutes of Health (NIH)
- Centers for Disease Control and Prevention (CDC)
- Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
- White Papers, Journals/Magazines, and News Articles
- Paid Databases, such as Factiva, D&B Hoovers, and Bloomberg Business
Report Objectives
- To define, describe, segment, and forecast the global CLIA market by product type, technology, sample type, application, end user, and region.
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall CLIA market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the CLIA market in five main regions, along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players in the global CLIA market and comprehensively analyze their core competencies and market shares.
- To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
- To benchmark players within the CLIA market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific CLIA market into Thailand, Indonesia, Philippines, Vietnam, Hong Kong, and other countries
- Further breakdown of the Rest of Europe CLIA market into Belgium, Russia, the Netherlands, Switzerland, and other countries.
- Further breakdown of the Rest of Latin America CLIA market into Argentina, Peru, and other countries.
Get the Full Chemiluminescence Immunoassay Market Report
Full forecast, segment splits, and company analysis for all Chemiluminescence Immunoassay Market.
- US Chemiluminescence Immunoassay Market
- Canada Chemiluminescence Immunoassay Market
- Germany Chemiluminescence Immunoassay Market
- France Chemiluminescence Immunoassay Market
- UK Chemiluminescence Immunoassay Market
- Italy Chemiluminescence Immunoassay Market
- Spain Chemiluminescence Immunoassay Market
- China Chemiluminescence Immunoassay Market
- Japan Chemiluminescence Immunoassay Market
- India Chemiluminescence Immunoassay Market
- South Korea Chemiluminescence Immunoassay Market
- Australia Chemiluminescence Immunoassay Market
- Brazil Chemiluminescence Immunoassay Market
- Mexico Chemiluminescence Immunoassay Market
- Rest Of Asia Pacific Chemiluminescence Immunoassay Market
- Rest Of Latin America Chemiluminescence Immunoassay Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report